Clinical data
Participant demographic information, past medical history, comorbidities, inflammatory markers, high sensitivity (HS) troponin levels, outpatient medications, and inpatient therapies were collected from the electronic medical record. In addition, data on the need for mechanical ventilation, duration of mechanical ventilation, intensive care unit and hospital lengths of stay, and in-hospital mortality was obtained. To standardize vasopressor dosing across participants receiving different agents, the cumulativeĀ dose of norepinephrine equivalents (NE Eq) was calculatedĀ as has been described previously12, 13 with a conversion factor for angiotensin II of 1 ng per 0.1 mcg of norepinephrine based upon the ATHOS-3 trial (Supplement Table 1).13 All 12 lead electrocardiograms (ECGs) recorded during admission were reviewed by a board certified cardiologist to determine the development of atrial arrhythmias. Participants with ECG documentation of a new-onset atrial fibrillation, atrial flutter, or atrial tachycardia were labeled as having an ATA.